20 ml

Arbutin Dark Spots

Cremigel based on a high concentration of arbutin (5%) and glycyrrhetinic acid (enoxolone) that helps brighten and even skin tone. This synergistic combination works by reducing the appearance of dark spots to improve the complexion. Lightweight, fast-absorbing formula.

Cremigel based on a high concentration of arbutin (5%) and glycyrrhetinic acid (enoxolone) that helps brighten and even skin tone. This synergistic combination works by reducing the appearance of dark spots to improve the complexion. Lightweight, fast-absorbing formula.

Basic information

Daily
Day/Night
All skin types
20 ml

Arbutin

Depigmenting effect.

Enoxolone

Soothes and repairs.

DELIVERY
Receive it in 48/72 working hours (to domicile)


SHIPPING COSTS
4,50€ for orders less than 39€.
FREE from 39€ and above

Aqua (Water), Arbutin, Dimethicone, Propanediol, Silica, Dibutyl Adipate, Ethoxydiglycol, PEG-8, Ammonium Acryloyldimethyltaurate/VP Copolymer, Glycyrrhetinic Acid, Diethylhexyl Syringylidenemalonate, Sodium Lactate, Tocopherol, Isoceteth-20, Phenylpropanol,Caprylyl Glycol, Dimethicone Crosspolymer, Disodium EDTA, Caprylic/Capric Triglyceride, Sodium Hydroxide, Benzyl Alcohol, Parfum (Fragrance), CI 16035 (Red 40), CI 19140 (Yellow 5), CI 42090 (Blue 1)

Application mode

Application mode

Apply a small amount of product to clean, dry skin in the morning and/or at night. Can be applied after using other products to maximise the end result. For best results, we recommend using a high protection sunscreen (SPF 50+) by day.

Clinical studies

Test clínico de Arbutin Dark Spots

90% more even skin

87% Say it lightens dark spots

90% of participants said their skin looked brighter.

37 of participants said their skin tone was more even.*

Clinical study on 30 men and women aged 29 to 60 under dermatological control at an independent centre. Participants evaluated its efficacy subjectively after applying the product twice a day, morning and night, for 56 days. *Determination of moisturising efficacy using a mexameter on a subgroup of 22 participants. Dermatologically tested.